Skip to content
HowShorted

Aligos Therapeutics, Inc. short interest in 2021

In 2021, Aligos Therapeutics, Inc.'s disclosed short interest ran from 3.29% of shares outstanding on 15 Jan 2021 to 5.30% on 31 Dec 2021, a change of +2.01 percentage points. The year's high was 5.30% on 31 Dec 2021 and its low 3.29% on 15 Jan 2021, averaging 4.31% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 32.27 days on 31 Mar 2021. Full history: Aligos Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Aligos Therapeutics, Inc. in 2021

2021 in figures

Start of year
3.29% (15 Jan 2021)
End of year
5.30% (31 Dec 2021)
Change
+2.01 pp
High
5.30% (31 Dec 2021)
Low
3.29% (15 Jan 2021)
Average
4.31%
Highest days to cover
32.27 (31 Mar 2021)
SEC filings marked
8

Every report in 2021

Aligos Therapeutics, Inc. short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 20213.29%17.34
29 Jan 20213.44%16.12
12 Feb 20213.58%21.80
26 Feb 20213.94%18.41
15 Mar 20214.07%31.24
31 Mar 20214.06%32.2710-K filed, results (8-K)
15 Apr 20214.20%27.46
30 Apr 20214.27%27.06
14 May 20214.22%31.2810-Q filed, results (8-K)
28 May 20214.11%16.61
15 Jun 20214.09%14.09
30 Jun 20214.48%6.59
15 Jul 20214.62%2.83
30 Jul 20214.84%7.11
13 Aug 20214.38%9.1810-Q filed, results (8-K)
31 Aug 20214.22%16.37
15 Sep 20214.07%4.45
30 Sep 20214.46%7.55
15 Oct 20214.55%11.59
29 Oct 20214.67%14.60
15 Nov 20214.51%11.2010-Q filed, results (8-K)
30 Nov 20214.99%20.56
15 Dec 20215.12%11.78
31 Dec 20215.30%7.73

See also: Aligos Therapeutics, Inc.'s full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.